A Novel Approach for Nasopharyngeal Carcinoma Treatment Uses Phenylbutyrate as a Protein Kinase C Modulator: Implications for Radiosensitization and EBV-targeted Therapy

• Published in: Clinical cancer research 2000-04, Vol.6 (4), p.1452-1458
• Main Authors: CHUNG, Y.-L, WU LEE, Y.-H, YEN, S.-H, CHI, K.-H
• Format: Article
• Language: English
• Subjects: Antineoplastic agents; Antiviral Agents - pharmacology; Biological and medical sciences; Cell Division - drug effects; Cell Division - radiation effects; Cell Survival - drug effects; Cell Survival - radiation effects; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Dose-Response Relationship, Radiation; Epstein-Barr Virus Infections - drug therapy; Epstein-Barr Virus Infections - virology; Ganciclovir - pharmacology; Herpesvirus 4, Human - enzymology; HL-60 Cells; Humans; Medical sciences; Nasopharyngeal Neoplasms - drug therapy; Nasopharyngeal Neoplasms - pathology; Otorhinolaryngology. Stomatology; Pharmacology. Drug treatments; Phenylbutyrates - pharmacology; Protein Kinase C - drug effects; Protein Kinase C - metabolism; Radiation-Sensitizing Agents - pharmacology; Telomerase - drug effects; Telomerase - metabolism; Thymidine Kinase - drug effects; Thymidine Kinase - metabolism; Tumor Cells, Cultured - drug effects; Tumor Cells, Cultured - radiation effects; Tumor Cells, Cultured - virology; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
• ISSN: 1078-0432; 1557-3265

Sodium phenylbutyrate (NaPB) represent a new nontoxic class of compounds with antiproliferative activities to different tumors and has been shown to modulate many gene expressions by inhibiting histone deacetylation and DNA methylation as the major mechanism. Butyrate and other protein kinase C (PKC) activators have been reported to be able to activate virus enzymes. The present work investigates whether NaPB has an antiproliferative effect or modulatory effects on EBV-associated nasopharyngeal carcinoma (NPC) and whether EBV thymidine kinase gene can be activated to make cells susceptible to ganciclovir (GCV) therapy. NaPB treatment displayed a dose- and time-dependent antiproliferative effect on the NPC cell line CNE2. Cell cycle analysis revealed an inhibitory effect of NaPB on G 1 -S-phase progression. Shortly after NaPB treatment, we found that PKC activity was activated rapidly but also decreased rapidly. Down-regulation of PKC-α and translocation of PKC-α from the cytosol to membrane were seen by Western blot. The decrease in PKC activity by NaPB corresponds to an enhanced response to radiation on CEN2 cells. Moreover, NaPB up-regulated EBV thymidine kinase activity to render EBV-associated Daudi cells susceptible to killing by GCV. Based on the observations of NaPB as a PKC modulator, the combination of NaPB, GCV, and radiation may provide a potential novel approach for treatment of EBV-associated NPC.